Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

FDA Guidance Development Offers Model For CMS – Device Stakeholders

This article was originally published in The Gray Sheet

  • News

Executive Summary

CMS should assimilate FDA's policy of engaging industry early in the guidance development process, according to device stakeholders

You may also be interested in...



CMS To Develop Guidance On Coverage Decisions Requiring Registries

CMS' emerging policy of attaching clinical trial or registry requirements as a condition of coverage will be clarified in an upcoming guidance

CMS To Develop Guidance On Coverage Decisions Requiring Registries

CMS' emerging policy of attaching clinical trial or registry requirements as a condition of coverage will be clarified in an upcoming guidance

Medicare Tech Council Launch: White Paper, Guidance Documents Planned

CMS' Council on Technology & Innovation is developing a white paper to elucidate the agency's coverage, coding and payment processes

Table

View full table

Tags:
Latest Headlines

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

See All
UsernamePublicRestriction

Register

MT020972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By